Formulation: A solid
Formal Name: (7S)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide
Purity: ≥98%
Formula Markup: C27H29N5O3
Formula Weight: 471,6
Shelf life (days): 1460
CAS Number: 1691249-45-2
Notes: Zanubrutinib is a potent and covalent inhibitor of Bruton's tyrosine kinase (BTK; IC50 = 0.3 nM).{52108} It is selective for BTK over a panel of 304 kinases at 1 μM but does inhibit EGFR, Tec, Blk, BMX, HER4, and TXK (IC50s = 0.62-33 nM). Zanubrutinib inhibits phosphorylation of BTK at Y233 (IC50 = 1.8 nM) in Ramos cells and reduces viability of REC-1 cells (IC50 = 0.36 nM). In vivo, zanubrutinib (2.5 and 7.5 mg/kg) reduces tumor volume in an OCI-LY10 diffuse large B cell lymphoma (DLBCL) mouse xenograft model.